Talis Biomedical (NASDAQ:TLIS) Trading 2.1% Higher

Talis Biomedical Co. (NASDAQ:TLIS) shares traded up 2.1% during trading on Friday . The company traded as high as $8.90 and last traded at $8.80. 9,272 shares were traded during trading, an increase of 15% from the average session volume of 8,030 shares. The stock had previously closed at $8.62.

Talis Biomedical Price Performance

The stock has a market cap of $16.03 million, a P/E ratio of -0.28 and a beta of 1.69. The business’s 50 day simple moving average is $8.96 and its 200 day simple moving average is $8.49.

Talis Biomedical (NASDAQ:TLIS) last posted its earnings results on Wednesday, May 8th. The company reported ($7.15) earnings per share (EPS) for the quarter. Talis Biomedical had a negative net margin of 5,784.73% and a negative return on equity of 75.40%. The firm had revenue of $0.07 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Talis Biomedical stock. BML Capital Management LLC acquired a new position in Talis Biomedical Co. (NASDAQ:TLIS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 42,743 shares of the company’s stock, valued at approximately $318,000. BML Capital Management LLC owned about 2.35% of Talis Biomedical at the end of the most recent reporting period. 43.77% of the stock is currently owned by institutional investors.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.